Theia Medical Secures $1 Million MTPConnect TTRA Devices Grant

Congratulations to Associate Professor Jiawen Li, IPAS member and founder of Theia Medical Pty Ltd, on securing $1 million in funding through MTPConnect’s Targeted Translation Research Accelerator (TTRA) Devices Investment Program.

Theia Medical’s award-winning innovation is a hybrid 3D-printed intravascular imaging device that combines multimodal imaging technologies to improve the detection of high-risk coronary artery disease. By enabling more accurate characterisation of dangerous plaque, this technology has the potential to transform early diagnosis and guide more effective treatment for patients with coronary artery disease, one of the world’s leading causes of death.

This success is part of MTPConnect’s broader announcement of $12 million in funding across 14 Australian life science companies, aimed at tackling chronic health challenges like cardiovascular disease and diabetes. The announcement was made during the BIO International Convention in Boston, a major global event for the biotechnology industry.

This achievement is a testament to the impact of translational research at IPAS, moving innovations from the optical bench to real-world clinical solutions. It also reflects the strength of collaboration between our researchers, the University of Adelaide’s medical community, and the broader ecosystem of innovation and commercialisation.

Learn more about Theia Medical and the MTPConnect TTRA program